undamentalytics Newsletter
Sign in

Mimedx Group, Inc. (MDXG) stock

Add to watchlist

Add holding +

NASDAQ: MDXG Nasdaq Health Care Supplies Next results ~January 27, 2027

C Fundamentals grade

Mimedx Group, Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$4.2

Cash-flow model

Base case. Range ~$3.4–$5.3 across our lower- and higher-growth cases (-1%–9% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 28% above it.

Price used: $3.28, November 2, 2026

Mimedx Group, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds128 adding, 108 cuttingOf 43 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Mimedx Group files

Where Mimedx stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $304m, down 22.8% on a year earlier, a steeper fall than the 2.4% decline a quarter earlier. That puts it 11 of 11 for growth among the health care supplies companies we cover. Free-cash-flow margin fell to 2.0% from 15.7% a year earlier. Operating margin narrowed to -8.3% from 13.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 5 of our 6 financial-health checks. Our cash-flow model value is $4.13 a share, against a share price of $3.67.

Source: 10-Q filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 27, 2027 (estimated)

Mimedx Group, Inc.'s trailing-twelve-month revenue fell 22.8% year on year, with a free-cash-flow margin of 2.0%. Where it stands out: gross margin of 77.3% ranks 1 of 13 health care supplies companies we cover. Where it lags: change in growth rate of -20.4pp ranks 13 of 13 health care supplies companies we cover.

Our discounted-cash-flow model values the business at ~$4.2 per share in the base case (~$3.4–$5.3 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -22.8% (-20.4pp vs the prior quarter), the 3rd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $3.28 is 28% below our value per share of $4.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Revenue shrinking. Revenue fell 22.8% over the last 12 months.
  • Growth slowing. The growth rate is 20.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -8.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 22.0 points on a year ago.
  • Gross margin slipping. Gross margin is down 4.7 points on a year ago.
  • Below peers: free-cash-flow margin. Free-cash-flow margin of 2.0% ranks 10 of 13 health care supplies companies we cover (median 6.7%).

Latest results: FY2026 Q3

Filed October 28, 2026
Earnings per share
-$0.01 against an average estimate of $0.00: beat by 0.0%
Revenue
$62m, down 45.2% on a year earlier
Share reaction
+1.8% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Next report
October 28, 2026; average EPS estimate $0.03

Mimedx Group's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-15.5%
  • 1 week-14.8%
  • 1 month-28.5%
  • This year-51.6%
  • 1 year-57.1%
  • 5 years-59.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$304M
Operating margin
-8.3%
Net margin
-6.3%
EPS (TTM, diluted)
$-0.13

Growth

Revenue growth
−22.8%
Change in growth rate
−20.4 pts
Share count change
−0.9%

Cash

Free cash flow (TTM)
$6.2M
FCF margin
2.0%
Stock pay % of revenue
1.6%

Earnings

Last results
October 28, 2026
Next results (est.)
January 27, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Results
  4. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Mimedx Group, Inc. valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 1.4% a year for five years.That is slower than the 4.6% a year revenue growth Mimedx Group has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in-1.4%
  • Last 12 months-22.8%
  • 3 years a year-0.6%
  • 5 years a year4.6%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($3.25, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$4.2
Price used
$3.25close November 3, 2026
Implied change
▲ +29%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Mimedx Group, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($25.8M, FY2026 Q3 TTM), growing -0.4% and 7.6% in the next two years (forecasts, guidance and its record), then back to 4% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$3.3–~$5.3 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Mimedx Group, Inc.'s free cash flow after stock-based pay ( $25.8M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Mimedx Group, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.83 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$4.2 ~$3.4–$5.3 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.1 ~$1.2–$2.0 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$3.2 ~$1.1–$4.2 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Mimedx Group, Inc. with Health Care Supplies in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −13%
  • Revenue growth 5 points higher ▲ +17%
  • Free-cash-flow margin 1 point lower ▼ −20%
  • Last year's free-cash-flow margin change, if it persists ▼ −74%
  • Discount rate 1 point higher ▼ −7%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $3$4$6$7$9$12
8.5% $3$3$4$5$7$9
10% $2$3$4$4$6$7

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$8.86$12.61$1.79$7.58$9.08$6.04$2.78$8.77$9.62$6.77$3.28
Market value$998m$1.5bn$189m$811m$983m$667m$314m$1.3bn$1.4bn$1.0bn$486m
+ Net debt (− = net cash)−$30m−$27m−$45m$4m−$46m−$37m−$16m−$32m−$85m−$148m−$121m
Enterprise value$968m$1.4bn$144m$815m$937m$629m$298m$1.2bn$1.3bn$866m$365m
Multiples
Price / sales 4.5x4.6x0.5x2.7x4.0x2.8x1.2x4.0x4.1x2.4x1.6x
Price / earnings n/m22.6x—————22.0x33.8x20.9x—
Price / free cash flow ———————51.6x21.7x13.7x23.4x
EV / EBITDA n/m28.6x73.5x————30.8x20.8x11.0x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

59 /100

Moderate moat

How hard Mimedx Group's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 19 / 20

    Cash operating profit has been a median 14.6% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 83.3%, moving by 3.3 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -8.0%; its worst year was -13.3%.

  • Cash conversion 9 / 20

    Free cash flow was positive in 4 of 5 years, at a median 2.8% of revenue.

  • Discipline 6 / 20

    The diluted share count rose 34.8% over five years; stock-based pay has been a median 4.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (64 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.10 −122% $257m −39%
Next $0.11 +207% $305m +19%

Next year's EPS estimate has moved −38.5% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +87.5% on 90 days ago. In the last 30 days, 0 analysts raised Mimedx Group, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Mimedx Group, Inc., last 90 days
−$0.10 $0.00 $0.10 $0.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.05 Current fiscal year, 60 days ago: −$0.05 Current fiscal year, 30 days ago: −$0.06 Current fiscal year, 7 days ago: −$0.08 Current fiscal year, Now: −$0.10 −$0.10 Next fiscal year, 90 days ago: $0.17 Next fiscal year, 60 days ago: $0.10 Next fiscal year, 30 days ago: $0.10 Next fiscal year, 7 days ago: $0.10 Next fiscal year, Now: $0.11 $0.11

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.05$0.17
60 days ago −$0.05$0.10
30 days ago −$0.06$0.10
7 days ago −$0.08$0.10
Now −$0.10$0.11

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.00 −$0.01 0.0%
Jun 2026 −$0.03 −$0.05 −50.0%
Mar 2026 −$0.04 −$0.05 −33.3%
Dec 2025 $0.11 $0.14 +30.2%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Mimedx Group, Inc.'s revenue by -0.4% next year and +7.6% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (-3.4%, weight 60%) and the company's own record (+4.0%, weight 40%) . How the weights are set.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026145
  2. Sep 2026145
  3. Aug 2026145
  4. Jul 2026145

Counts of recommendations published by analysts covering Mimedx Group, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.0%
of tradable shares
Days to cover
7.99
at average volume
Short interest, 1 month
−14%
to October 15, 2026
Held by institutions
78%
of shares
Held by insiders
2.1%
of shares
Employees
808
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −57.1%

$7.65 on October 31, 2025 to $3.28

ThenNowEffect
Revenue (last 12 months) $364m $355m −2.4%
Net margin 8.8% 1.8% −80.1%
P/E multiple 35.4x 78.4x +121.1%
Share count 149m 149m 0.0%

Biggest factor: net margin.

Last 3 years −51.9%

$6.82 on November 3, 2023 to $3.28

ThenNowEffect
Revenue (last 12 months) $295m $355m +20.4%
P/S multiple 2.8x 1.4x −51.2%
Share count 122m 149m −18.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MDXG−34%−54%+216%+10%−30%−52%
Industry peers (median)+19%−45%+22%−13%−13%−7%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MDXG67%33%67%50%17%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MDXG−65%−58%−35%−37%−40%−54%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from January 29, 2018 to December 7, 2018. Getting back needed a 1462% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.09 – $7.96
From 52-week high
−58.8%
vs 50-day average
−26.5%
vs 200-day average
−23.0%
Volatility (1 year)
44%
Beta vs S&P 500
0.85

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±7.4%
After a week
7 up, 4 down
typical move ±10.5%
After a month
5 up, 6 down
typical move ±13.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +1.8% 0.0% — —
July 29, 2026 −2.1% +0.1% −4.6% +3.4%
April 29, 2026 −1.2% +1.0% +7.6% +8.2%
February 25, 2026 −7.7% +0.3% −9.9% −26.4%
October 29, 2025 +7.6% −1.1% +15.7% 0.0%
July 30, 2025 +7.8% −0.5% +8.5% +7.6%
April 30, 2025 −8.7% +0.7% +0.9% −7.1%
February 26, 2025 +2.3% −1.5% +1.6% −2.8%
October 30, 2024 +17.9% −2.3% +29.1% +59.2%
July 31, 2024 −12.0% +0.2% −17.4% −11.9%
April 30, 2024 +16.8% −1.9% +16.5% +13.7%
February 28, 2024 −2.9% +0.2% −3.9% −8.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Mimedx Group, Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade C (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Mimedx Group, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Mimedx Group, Inc.
$300M $350M $400M $450M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $321.5M Revenue (TTM), FY24 Q1: $334.5M Revenue (TTM), FY24 Q2: $340.5M Revenue (TTM), FY24 Q3: $342.8M Revenue (TTM), FY24 Q4: $348.9M Revenue (TTM), FY25 Q1: $352.4M Revenue (TTM), FY25 Q2: $363.8M Revenue (TTM), FY25 Q3: $393.4M Revenue (TTM), FY25 Q4: $418.6M Revenue (TTM), FY26 Q1: $389.4M Revenue (TTM), FY26 Q2: $355.2M Revenue (TTM), FY26 Q3: $303.7M $303.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $321.5M
FY24 Q1 $334.5M
FY24 Q2 $340.5M
FY24 Q3 $342.8M
FY24 Q4 $348.9M
FY25 Q1 $352.4M
FY25 Q2 $363.8M
FY25 Q3 $393.4M
FY25 Q4 $418.6M
FY26 Q1 $389.4M
FY26 Q2 $355.2M
FY26 Q3 $303.7M
Revenue growth, TTM YoY Mimedx Group, Inc.
-40% -20% 0% 20% 40% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 20.0% Revenue growth, TTM YoY, FY24 Q1: 19.2% Revenue growth, TTM YoY, FY24 Q2: 15.4% Revenue growth, TTM YoY, FY24 Q3: 10.9% Revenue growth, TTM YoY, FY24 Q4: 8.5% Revenue growth, TTM YoY, FY25 Q1: 5.3% Revenue growth, TTM YoY, FY25 Q2: 6.8% Revenue growth, TTM YoY, FY25 Q3: 14.8% Revenue growth, TTM YoY, FY25 Q4: 20.0% Revenue growth, TTM YoY, FY26 Q1: 10.5% Revenue growth, TTM YoY, FY26 Q2: -2.4% Revenue growth, TTM YoY, FY26 Q3: -22.8% -22.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 20.0%
FY24 Q1 19.2%
FY24 Q2 15.4%
FY24 Q3 10.9%
FY24 Q4 8.5%
FY25 Q1 5.3%
FY25 Q2 6.8%
FY25 Q3 14.8%
FY25 Q4 20.0%
FY26 Q1 10.5%
FY26 Q2 -2.4%
FY26 Q3 -22.8%
Operating margin (TTM) Mimedx Group, Inc.
-10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 11.5% Operating margin (TTM), FY24 Q1: 15.1% Operating margin (TTM), FY24 Q2: 18.6% Operating margin (TTM), FY24 Q3: 18.5% Operating margin (TTM), FY24 Q4: 16.9% Operating margin (TTM), FY25 Q1: 15.3% Operating margin (TTM), FY25 Q2: 11.8% Operating margin (TTM), FY25 Q3: 13.7% Operating margin (TTM), FY25 Q4: 15.3% Operating margin (TTM), FY26 Q1: 10.2% Operating margin (TTM), FY26 Q2: 2.5% Operating margin (TTM), FY26 Q3: -8.3% -8.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 11.5%
FY24 Q1 15.1%
FY24 Q2 18.6%
FY24 Q3 18.5%
FY24 Q4 16.9%
FY25 Q1 15.3%
FY25 Q2 11.8%
FY25 Q3 13.7%
FY25 Q4 15.3%
FY26 Q1 10.2%
FY26 Q2 2.5%
FY26 Q3 -8.3%
FCF margin (TTM) Mimedx Group, Inc.
0% 5% 10% 15% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 7.7% FCF margin (TTM), FY24 Q1: 10.0% FCF margin (TTM), FY24 Q2: 14.0% FCF margin (TTM), FY24 Q3: 15.9% FCF margin (TTM), FY24 Q4: 17.2% FCF margin (TTM), FY25 Q1: 16.9% FCF margin (TTM), FY25 Q2: 14.3% FCF margin (TTM), FY25 Q3: 15.7% FCF margin (TTM), FY25 Q4: 14.1% FCF margin (TTM), FY26 Q1: 14.3% FCF margin (TTM), FY26 Q2: 8.8% FCF margin (TTM), FY26 Q3: 2.0% 2.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 7.7%
FY24 Q1 10.0%
FY24 Q2 14.0%
FY24 Q3 15.9%
FY24 Q4 17.2%
FY25 Q1 16.9%
FY25 Q2 14.3%
FY25 Q3 15.7%
FY25 Q4 14.1%
FY26 Q1 14.3%
FY26 Q2 8.8%
FY26 Q3 2.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Mimedx Group took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $419M
  2. Other income $2.4M · 0.6%
  3. Cost of revenue $73M · 17.4%
  4. Gross profit $346M · 82.6%
  5. Research and development $15.1M · 3.6%
  6. Selling, general and admin $266M · 63.6%
  7. Operating income $63.9M · 15.3%
  8. Income tax $17.7M · 4.2%
  9. Net income $48.6M · 11.6%

Shares of revenue. Source: Mimedx Group's 10-K for FY2025, as filed with the SEC. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 1 8 222 321 359 299 248 242 268 321 349 419 304
Gross profit — 4 191 286 323 256 209 202 220 267 289 346 235
EBITDA −10 −9 4 50 2 −15 −40 −3 −11 41 65 79 −11
Operating income −11 −10 1 46 −4 −21 −45 −7 −15 37 59 64 −25
Net income −11 −10 0 65 −30 −26 −49 −10 −30 58 42 49 −19
Diluted EPS −$0.19 −$0.14 $0.00 $0.56 −$0.28 −$0.24 −$0.77 −$0.15 −$0.33 $0.37 $0.28 $0.32 −$0.13
Growth (year on year)
Revenue — +883.7% +>999% +44.8% +11.8% −16.7% −17.0% −2.5% +10.7% +20.0% +8.5% +20.0% −22.8%
EBITDA — — — — −96.1% — — — — — +60.1% +21.4% −117.7%
Operating income — — — — −108.5% — — — — — +58.6% +8.5% −146.7%
Net income — — — — −146.3% — — — — — −27.2% +14.5% −147.0%
Diluted EPS — — — — −150.0% — — — — — −24.3% +14.3% −147.4%
Margins
Gross margin — 56.7% 86.0% 89.0% 89.9% 85.6% 84.2% 83.6% 82.0% 83.0% 82.8% 82.6% 77.3%
EBITDA margin <−999% −120.0% 1.9% 15.7% 0.5% −4.9% −16.0% −1.1% −4.2% 12.6% 18.6% 18.8% −3.5%
Operating margin <−999% −125.8% 0.4% 14.4% −1.1% −7.1% −18.3% −2.9% −5.5% 11.5% 16.9% 15.3% −8.3%
Net margin <−999% −131.4% 0.2% 20.2% −8.3% −8.5% −19.9% −4.2% −11.3% 18.1% 12.2% 11.6% −6.3%
Free-cash-flow margin — — — — — — — −2.1% −7.2% 7.7% 19.0% 17.7% 6.8%
Cash flow
Cash from operations −8 −7 24 63 36 −39 −30 −2 −18 27 66 74 21
Capital spending — — — — — — — 3 2 2 0 0 0
Free cash flow — — — — — — — −5 −19 25 66 74 21
Stock-based pay 1 2 18 21 15 12 15 14 11 17 17 16 5
Free cash flow after stock pay — — — — — — — −19 −31 8 49 58 16
Balance sheet
Cash 1 4 30 27 45 69 96 87 66 82 104 166 121
Total debt 0 8 0 0 0 73 50 50 50 50 19 18 0
Net debt (negative = net cash) −1 4 −30 −27 −45 4 −46 −37 −16 −32 −85 −148 −121
Diluted shares — 72m 113m 116m 106m 107m 108m 110m 113m 146m 149m 150m 148m
Returned to shareholders
Buybacks — — 10 68 8 0 1 0 0 10 0 0 —
Total returned — — 10 68 8 0 1 0 0 10 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 6 checks passed · September 30, 2026
What it owns · $265m
Short-term assets $187mLonger-term assets $77m
What it owes, and who funded it · $265m
Short-term liabilities $43mLonger-term liabilities $10mShareholders' equity $211m
  • Short-term assets cover short-term liabilities $187m of assets due within a year against $43m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $187m short-term assets against $10m of longer-dated liabilities.
  • More cash than debt $121m of cash against $0 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt No debt to cover.
  • Operating profit covers interest at least five times over Operating income of −$25m against $2m of interest.

From Mimedx Group, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$9.5M
Diluted share count
−0.9%
year over year
R&D spending
4.8%
of revenue
Sales & admin spending
80.5%
of revenue
Days sales outstanding
45 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care supplies
Last 12 months unless stated MDXG ORGO UFPT OSUR EMBC ICUI Median
Revenue, last 12 months $304m $457m $632m $112m $1.0bn $2.2bn $1.0bn
Revenue growth, last 12 months −22.8% 6.5% 7.3% −18.9% −7.6% −9.0% 3.4%
Revenue growth, 3-year average −0.6% 0.0% 17.8% −38.4% −2.9% −2.0% 0.0%
Revenue growth, latest quarter −45.2% −56.7% 15.1% −1.9% −8.1% 0.5% 0.6%
Gross margin 77.3% 75.9% 28.5% 42.6% 59.0% 39.1% 52.9%
Operating margin −8.3% −7.8% 15.3% −48.1% 21.9% 3.3% 3.3%
Operating margin, 3-year average 8.0% −5.2% 15.4% −28.5% 18.7% 2.2% 2.2%
Net margin −6.3% −18.4% 11.4% −43.7% 8.6% 1.4% 1.4%
Cash from operations / revenue 6.8% 7.0% 11.3% −38.1% 17.1% 10.9% 10.6%
Free-cash-flow margin 2.0% 4.6% 9.0% −42.8% 16.2% 6.7% 6.7%
Free-cash-flow margin, 3-year average 11.2% −1.4% 10.5% −8.5% 9.8% 5.2% 9.8%
Stock pay / revenue 1.6% 3.1% 1.6% 8.3% 2.5% 2.5% 2.5%
Change in share count −0.9% 1.7% 0.2% −4.9% 0.6% 2.5% −0.4%

Median of all 13 companies we cover in health care supplies. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care supplies companies
Measure Company Peer median Rank
Revenue growth Growth -22.8% 3.4% 12 of 13
Change in growth rate Growth -20.4pp -0.3pp 13 of 13
Gross margin Profitability 77.3% 52.9% 1 of 13
Operating margin Profitability -8.3% 3.3% 9 of 13
Net margin Profitability -6.3% 1.4% 8 of 13
Free-cash-flow margin Cash generation 2.0% 6.7% 10 of 13
Stock pay as % of revenue Cash generation 1.6% 2.5% 5 of 13
Long-term debt as % of assets Balance sheet 0.0% 15.4% 1 of 9
Change in share count Balance sheet -0.9% 0.1% 6 of 12
Days sales outstanding Balance sheet 45 days 65 days 3 of 11

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Wound $276M 66.0% ▲ 19.6%
Surgical $142M 34.0% ▲ 20.7%

From Mimedx Group, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$449M
Institutions reporting
226
Shares held vs prior quarter
▲ 3.3%
Positions opened / closed
41 / 48

Top buyers and sellers, Q2 2026: 128 institutions bought and 108 sold ; the biggest buyer was Nantahala Capital Management, LLC (+6.1M shares) and the biggest seller First Light Asset Management, LLC (−2.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Essex Woodlands Management, Inc. $109M 28.2M 24.2% 0.0%
Blackrock, Inc. $46.8M 12.2M 10.4% ▲ 2.0%
Nantahala Capital Management, LLC $36.7M 9.5M 8.2% ▲ 180.7%
Trigran Investments, Inc. $27.6M 7.2M 6.2% 0.0%
State Street Corp $21.5M 5.6M 4.8% ▲ 10.3%
Vanguard Capital Management LLC $20M 5.2M 4.4% ▲ 0.4%
Paradigm Capital Management Inc $15.7M 4.1M 3.5% ▲ 19.4%
Geode Capital Management, LLC $12.1M 3.1M 2.7% ▲ 9.1%
Goldman Sachs Group Inc $10.3M 2.7M 2.3% ▲ 124.8%
AQR Capital Management LLC $9.5M 2.5M 2.1% ▲ 170.3%
Renaissance Technologies LLC $9.4M 2.4M 2.1% ▼ 19.1%
Punch & Associates Investment Management, Inc. $7.9M 2.1M 1.8% ▲ 1.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Mimedx Group, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Mimedx Group, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Tom Malinowski(D-NJ 7):Sale (full), $15,001 - $50,000, traded May 30, 2019, filed July 9, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 27, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • July 29, 2026
  • April 29, 2026
  • February 25, 2026
  • October 29, 2025
  • July 30, 2025

Recent SEC filings

Data status

When each part of this page on Mimedx Group, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Mimedx Group, Inc. in brief

What does Mimedx Group, Inc. do?
Mimedx Group, Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.
What is Mimedx Group, Inc.'s stock ticker?
Mimedx Group, Inc. trades under the ticker MDXG on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Mimedx Group, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Mimedx Group, Inc. reported revenue of $304M, 22.8% lower than a year earlier, according to its SEC filings.
What is Mimedx Group, Inc.'s free cash flow?
Mimedx Group, Inc.'s free-cash-flow margin is 2.0% of revenue over the trailing twelve months, ranking 10 of the 13 health care supplies companies we cover.
What is Mimedx Group, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Mimedx Group, Inc.'s free cash flow after stock-based pay gives ~$4.2 per share in the base case, and ~$3.4–$5.3 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Mimedx Group, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Essex Woodlands Management, Inc., Blackrock, Inc. and Nantahala Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Mimedx Group, Inc.'s market cap?
On November 2, 2026, Mimedx Group, Inc.'s market capitalisation was about $486M and net debt of -$121M. Market figures come from third-party market data and may be delayed.
How much debt does Mimedx Group, Inc. have?
Mimedx Group, Inc.'s debt-to-equity ratio is 0.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Mimedx Group, Inc.'s competitors?
In our Health Care Supplies peer group, the companies closest to Mimedx Group, Inc. are Organogenesis Holdings Inc., UFP Technologies Inc, Orasure Technologies Inc, Embecta Corp. and ICU Medical Inc. The side-by-side comparison below sets their revenue, margins and growth against Mimedx Group, Inc.'s.
When is Mimedx Group, Inc.'s next earnings date?
Around January 27, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Mimedx Group, Inc. announces its own schedule.